Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Customized Viral Immunotherapy for HPV-Associated Cancer.

Cancer immunology research - 1 Oct 2017

Atherton Matthew J, Stephenson Kyle B, Pol Jonathan, Wang Fuan, Lefebvre Charles, Stojdl David F, Nikota Jake K, Dvorkin-Gheva Anna, Nguyen Andrew, Chen Lan, Johnson-Obaseki Stephanie, Villeneuve Patrick J, Diallo Jean-Simon, Dimitroulakos Jim, Wan Yonghong, Lichty Brian D

Abstract excerpt

The viral-transforming proteins E6 and E7 make human papillomavirus-positive (HPV+) malignancies an attractive target for cancer immunotherapy. However, therapeutic vaccination exerts limited efficacy in the setting of advanced disease. We designed a strategy to induce substantial specific immune responses against multiple epitopes of E6 and E7 proteins based on an attenuated transgene from HPV serotypes 16 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviruses, Human
Share to Cancer Vaccines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytotoxicity, Immunologic

Share to Epitopes, T-Lymphocyte

Share to Oncogene Proteins, Viral

Share to Oncolytic Virotherapy

Share to Papillomavirus E7 Proteins

Share to Tumor Burden

Source

Identifiers

PMID: 28912369
DOI: 10.1158/2326-6066.CIR-17-0102

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Customized Viral Immunotherapy for HPV-Associated Cancer.PMID 28912369Read ↗

Design, Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope VaccineSemantic proximity Read ↗

Oncogenic viral antigens for engineered T cell immunotherapy: Challenges and opportunitiesSemantic proximity Read ↗

New mouse model based on adenocarcinoma 4T1 cells expressing HPV16 E6 and E7 applied to assess the efficacy of therapeutic and prophylactic E6/E7-based HPV16 vaccinesSemantic proximity Read ↗

Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated diseaseSemantic proximity Read ↗

A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumorsSemantic proximity Read ↗

Enhancing the Tumor Selectivity of a Picornavirus Virotherapy Promotes Tumor Regression and the Accumulation of Infiltrating CD8+ T Cells.Semantic proximity Read ↗

A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effectsSemantic proximity Read ↗

Adenovirus vector‐based prime‐boost vaccination via heterologous routes induces cervicovaginal CD8+ T cell responses against HPV16 oncoproteinsSemantic proximity Read ↗

Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 proteinSemantic proximity Read ↗

Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.Semantic proximity Read ↗

Development of a DNA Vaccine Targeting Human Papillomavirus Type 16 Oncoprotein E6Semantic proximity Read ↗

COVID-19 Vaccines: Bolstering Cancer TreatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.